Several RNA virus inhibitors were evaluated against simian (SAil) rotavirus infections in vitro and murine rotavirus gastroenteritis in vivo. Test compounds included 1-3-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin), 3-deazaguanine (3-DG), 3-deazauridine, and 9-(S)-(2,3-dihydroxypropyl)adenine [(S)-DHPA]. All drugs inhibited total infectious SAil virus yields in MA-104 cells. Ribavirin, 3-DG, and (S)-DHPA affected [3H]uridine uptake into uninfected MA-104 cells in both the acid-soluble and -insoluble fractions. All drugs reduced the levels of dense (precursor) and light (complete) SAil particle yields compared with controls but did not alter the relative amounts of dense compared with light particles, suggesting that the agents did not interfere with virus assembly. Ribavirin and 3-DG inhibited SAil polypeptide synthesis, as determined by polyacrylamide gel electrophoresis studies. None of the agents or mono-and triphosphate derivatives of ribavirin inhibited SAil RNA polymerase activity. In murine rotavirus studies, oral therapy with ribavirin-2',3',5'-triacetate and (S)-DHPA increased mean survival time, but no increase in survivor rate was observed. 3-DG-and (S)-DHPA-treated mice had a more rapid weight gain than controls, suggesting a probable lessening of the severity of the disease.
Reovirus-like agents (rotaviruses) have been associated with acute neonatal gastroenteritis in a number of animals, including humans (17, 26) . Attempts to prevent the disease with vaccines have been encouraging but not highly successful to date (25, 30) . Other methods have focused on treating the symptoms of the disease by parenteral replacement of fluids and electrolytes (13) . Two experimental attempts have been made to treat the disease with antiviral agents. Schoub and Prozesky (22) demonstrated that 1-1-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin) inhibited simian (SAl1) rotavirus cytopathic effect in vitro but was ineffective against murine rotaviral disease in mice. In a study we have reported previously (24) , the in vitro efficacies of ribavirin, 3-deazaguanine (3-DG), 3 -deazauridine (3-DU), and 9-(S)-(2,3-dihydroxypropyl)adenine [(S)-DHPA)] against bovine, porcine, and simian rotaviruses were determined. These results indicated 3-DG and ribavirin to be the most active rotaviral inhibitors of those examined; moderate antirotavirus activity was exhibited by (S)-DHPA and 3-DU. Of the three viruses evaluated, porcine rotavirus appeared to be least sensitive to the antiviral agents. The encouraging results of these studies led us to evaluate the compounds in more detail against the simian rotavirus in vitro to begin to determine their mechanisms of rotavirus inhibition and to study the most likely candidate compounds against murine rotavirus in vivo. These and all other radioisotopes used for studies in this report were purchased from ICN Chemical and Radioisotope Division, Irvine, Calif. Both the trichloroacetic acid-soluble and -insoluble portions were assayed by liquid scintillation, using methods we have described previously (24) . A continuous labeling assay was also performed, using ribavirin at 320 p.g/ml and (S)-DHPA at 1,000 ,ug/ml in [3H]uridine-treated cells (10 p.Ci of [3H]uridine per ml added concurrently with drug). Every 2 h, four wells of drug-treated cells and eight placebo wells of MA-104 cells in 96-well microplates (24) were solubilized with 10%o sodium dodecyl sulfate. After solubilization of all wells, the cells in solution were precipitated with 20%o trichloroacetic acid and processed for liquid scintillation analysis.
Dense and light particle synthesis. Particle synthesis experiments were performed by using confluent monolayers of MA-104 cells (10' . After 24 h of incubation, cells were scraped off and the cells and supernatants were Freon extracted as described above. Virus was then centrifuged into preformed cesium chloride gradients, and gradients were fractionated by bottom displacement by a recently published procedure (5) .
Study of SAll rotavirus polypeptide synthesis. Virus at 1 infectious unit per cell was propagated in 24-well microplates with or without drug and pulse-labeled for 11 to 13 h after infection with 50 ,uCi of 3H-amino acids per ml in amino acid-free medium. Cells were then solubilized with a solution containing 8 M urea, 2% pmercaptoethanol, and 1% sodium dodecyl sulfate (50 ,ul per well). Samples were boiled for 1 min, and then 10 ,ul of each sample was loaded on 9%o sodium dodecyl sulfate-polyacrylamide gels prepared by the method of Laemmli (15) . After being run, gels were prepared for fluorography (3) .
SAll RNA polymerase assay. Experiments were performed by the method of Cohen et al. (6) samples were placed in 20 ,ug of RNase (Sigma Chemical Co., St. Louis, Mo.) per ml. After 30 min, the RNase-treated samples were precipitated as described above. Filtration of all precipitates and counting by liquid scintillation were performed as described previously (24) . RNA polymerase activity was expressed as RNase-sensitive, acid-insoluble counts per minute.
Mouse studies. Table 1 . These results correlate with CPE inhibition data published previously (24) in that 3-DG had the strongest antiviral activity and 3-DU the least. (S)-DHPA exhibited a greater inhibition of total infectious virus yield than may have been predicted from the previous CPE inhibition experiments.
The data shown in (Table 3) , inhibition of acid-soluble and -insoluble counts per minute was evident as early as 2 to 4 h after starting the experiment.
The effect of drugs on dense (D) and light (L) SAl particle synthesis is shown in Fig. 1 . The D peak corresponds to precursor particles possessing three to four structural polypeptides, whereas the L peak represents complete rotavirions containing five or eight structural polypeptides (8, 29) . Primarily L particles were produced in this cell line. There was a decrease in the sizes of the light particle peaks and no significant buildup of dense particles, suggesting that the drugs did not interfere with D to L conversion, and therefore did not affect viral assembly.
In polyacrylamide gel electrophoresis studies (Fig. 2) , the far left lane shows the polypeptide band pattern of uninfected MA-104 cells. Adjacent to this is the lane representing virus-infected cell cultures. At high multiplicities of infection, cellular polypeptide synthesis was greatly inhibited, and only viral polypeptides were observed. The same band pattern is evident in all other lanes except those representing cultures Table 4 . None of the agents evaluated influenced viral polymerase activity by more than ±20o (P > 0.05) of the control, indicating that they caused no significant inhibition of the enzyme. concentrations used: ribavirin, 100 jig/ml; 3-DG, 10 ,ug/ml; 3-DU, 100 jig/ml; and (S)-DHPA, 100 ,ug/ml. D particle peak around fraction 8; L particle peak standardized at fraction 15. VOL. 21, 1982 band patterns for murine, human, and bovine rotaviruses. Although differing in minor aspects, as would be expected for different species isolates, the band patterns were sufficiently similar to indicate that the murine virus is a rotavirus.
In the in vivo studies, none of the agents caused a reduction in the number of mice with discernible diarrhea or caused an increase in the total number of survivors. However, ribavirin triacetate and (S)-DHPA increased mean survival time significantly. 3-DG-and (S)-DHPA-treated infected mice gained weight at a rate approaching that of the normal uninfected control (Fig. 4) statistical significance between groups could be established. Ribavirin triacetate may have been marginally toxic at the dose given, based upon one death and low weight gain observed in the uninfected, untreated animals. DISCUSSION The dose-response relationship between concentration of drug used and development of total infectious rotavirus particles correlated with degrees of CPE inhibition and immunofluorescent cell count reduction observed in our previous studies (24) . Although 3-DG caused the greatest degree of viral inhibition, (S)-DHPA was considered to be more effective because of its lower toxicity in vivo.
The effect of drug on [3H]uridine uptake indicated that ribavirin, 3-DG, and (S)-DHPA inhibited both acid-soluble and -insoluble fractions, and the degree of inhibition of the two fractions was nearly the same. Canonico et al. (4) [3H]uridine counts per minute was observed early in the course of treatment, the decrease in uptake of radiolabel cannot be attributed to merely having fewer viable cells in drug-treated wells compared with controls. Other biochemical studies on the effects of these compounds on cellular and DNA synthesis were presented previously (24) . Another antiviral substance, arildone, also inhibits [3H]uridine uptake into acidsoluble and -insoluble pools (18) .
The remaining in vitro studies were designed to elucidate possible mechanisms of drug action against SA1l rotavirus. In studying the effects of drug on virus assembly, it appears that none of the compounds affect the conversion of D (precursor) to L (complete) rotavirions. If an agent were to inhibit this conversion, one would have expected to see a large D and a reduced L particle peak, i.e. VOL. 21, 1982 translated viral mRNA, it is probable that ribavirin and 3-DG affect either the quantity or quality of viral mRNA. The possibility that ribavirin or its mono-and triphosphate derivatives affect the quantity of viral mRNA by directly inhibiting the SAl RNA polymerase can be ruled out by the data presented in Table  3 . The phosphorylated derivatives of 3-DG were not available for evaluation, however, so a direct inhibition of rotavirus polymerase by derivatives of 3-DG remains a possibility (27) .
Two other mechanisms of viral mRNA inhibition by ribavirin and 3-DG have been proposed in the literature. The first mechanism is the inhibition of cellular inosine 5'-monophosphate dehydrogenase by both agents (27, 28) , which, by lowering nucleotide levels intracellularly, could inhibit viral RNA synthesis in a nonspecific manner. Canonico and colleagues (4) recently have shown nucleotide levels in uninfected and Venezuelan equine encephalitis virus-infected cells to be the same, which suggests that inosine 5'-monophosphate dehydrogenase inhibition is not the primary mechanism of Venezuelan equine encephalitis virus inhibition. If a decrease in nucleotide levels in cells causes an inhibition of viral RNA synthesis, one would expect this decrease to inhibit cellular RNA synthesis as well, since the mechanism is nonspecific. But, for 3-DG especially (Table 2) , the effect of drug on [3H]uridine uptake is marginal at concentrations where SAl virus production (Table 1 ) and viral polypeptide synthesis (Fig. 2) are markedly inhibited. These data suggest that the inhibition of inosine 5'-monophosphate dehydrogenase is unrelated to antirotavirus activity.
Another mechanism of virus inhibition by ribavirin is the inhibition of capping of viral messenger RNA reported for vaccinia (9) and Venezuelan equine encephalitis (4) viruses. The lack of capping would render viral mRNA nonfunctional for translation to polypeptides but would not necessarily reduce the total amount of viral mRNA produced. Whether mRNA capping inhibition is the principal mechanism of SAl1 rotavirus inhibition by ribavirin or 3-DG remains to be determined.
The mechanism of action of 3-DU and (S)-DHPA against other viruses has not been elucidated (23), but (S)-DHPA is believed to inhibit the enzymatic activity of Rous sarcoma virus protein kinase (14) and vaccinia virus mRNA synthesis (19) . It is concluded from studies presented here that these agents do not inhibit simian rotavirus polypeptide synthesis and may not affect viral mRNA production, since polypeptides are translated from mRNA. No inhibition of viral RNA polymerase activity was evident when these compounds were present in the reaction mixture. Phosphorylated derivatives of 3-DU, which may be the biologically active forms (23), were unavailable for testing. The biologically active form of (S)-DHPA is most likely the form used for the polymerase assay, based upon its stability in vivo (14) . Virion assembly was not affected by these agents (Fig.  1) . The remaining possibility is that 3-DU and (S)-DHPA inhibit double-stranded genomic RNA synthesis. The possibility that ribavirin and 3-DG also inhibit double-stranded RNA synthesis cannot be ruled out either.
The antiviral activities observed against murine rotavirus infection were moderate at best. There are several possible explanations for the weak activity of the compounds against this disease. First, the mice only tolerated low concentrations of the drug for the length of treatment employed. We have used ribavirin triacetate and (S)-DHPA at much higher doses (500 mg/kg per day) in adult animals, but these infant mice were more sensitive to the compounds under these treatment conditions. Another possible explanation for the low degree of drug efficacy may be a drug distribution problem wherein a sufficient amount of agent was not present at the target organ to inhibit viral replication in the intestinal epithelial cells. A third possibility was suggested by Schoub and Prozesky (22) , who concluded that the antiviral activity of ribavirin may be reversed by the production of guanosine by mononucleotidases in the guts of mice. Since guanosine and other natural nucleotides are produced in the intestinal tract (11), a reversal of ribavirin triacetate, 3-DG, and (S)-DHPA activity by the substances may have occurred. Were these agents to remain in the intestinal tract for any length of time, they could also be metabolized (deaminated) to inactive forms by microbial enzymes (21) .
Of the four antiviral agents evaluated in this report, (S)-DHPA appears to have the greatest potential for use as an antirotavirus inhibitor in humans. The conclusion is based upon the marked effect of drug in vitro on virus production, the moderate in vivo effect of drug seen in these studies, and the low toxicity in larger animals as reported by others (7, 14) .
There is a clinically prolonged course of the rotaviral disease in many infants, caused by continued replication of virus in superficial epithelial cells of the small intestine. Theoretically, an antiviral agent, if administered relatively early in the infection, may be able to inhibit these cumulative effects of intestinal epithelial damage. Rotavirus vaccines are an alternative to using antiviral agents to control the disease, but these vaccines are still in the experimental stage of development (25, 30) . Vaccines are prophylactic rather than therapeutic, whereas antiviral
